Evotec
Peter Ingram is a seasoned scientist with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as a Senior Scientist 1 at Evotec since September 2015, Peter has held various roles within the company, including Senior Scientist and Discovery Scientist, where contributions were made to oncology projects and the training of new employees. Prior experience includes working as a Polymer Technologist at Regain Polymers Ltd and as a Sales Manager at GPE Scientific Ltd, where responsibilities included customer relations and equipment training. Peter's background also encompasses contract roles at Eli Lilly and a strong foundation in medicinal chemistry gained during a placement at UCB Pharma. Peter holds an MChem degree from the University of Leeds and has developed a diverse skill set throughout a dynamic career in scientific research and sales.
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.